


Sublingual immunotherapy linked to clinical benefits in HIV

August 4 2015



(HealthDay)—For grass pollen-allergic HIV-positive patients treated with highly-active antiretroviral therapy (HAART), sublingual immunotherapy (SLIT) is associated with significant clinical benefits, according to a study published online July 30 in *Allergy*.

Enrico Iemoli, Ph.D., from the Sacco Hospital in Milan, and colleagues examined the safety and [clinical effectiveness](#) of SLIT in a group of grass pollen-allergic HIV-positive patients treated with HAART. The authors compared 13 patients receiving SLIT tablets and symptomatic therapy with nine receiving symptomatic therapy alone. Analysis of total combined score (TCS), sum of symptom-medication score, and a quality of life (QoL) questionnaire were used to evaluate clinical benefits.

The researchers found that SLIT-treated patients had significant

improvement compared to controls in clinical efficiency data (TCS: $P = 0.0001$; QoL: $P = 0.03$). No significant alteration was seen in TCD4 cell counts or viral load in either group.

"Our preliminary data, in a small group of HIV-positive [patients](#), show that not only [is] the SLIT therapy clinically effective but it is safe and does not change any immune-virological parameter," the authors write.

More information: [Abstract](#)

[Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Sublingual immunotherapy linked to clinical benefits in HIV (2015, August 4) retrieved 4 May 2024 from

<https://medicalxpress.com/news/2015-08-sublingual-immunotherapy-linked-clinical-benefits.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--